AN OPEN-LABEL, PHASE 1B/2 STUDY INVESTIGATING RECOMMENDED PHASE 2 DOSE, SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF TAK-659 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML)
- Registry ID
- C34002
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- MILLENNIUM PHARMACEUTICALS INC
- Start date
- 2016-04-12
- Last update
- 2015-08-20
Conditions
- ACUTE MYELOGENOUS LEUKEMIA
Related clinical trials
- A PHASE 1/2 FIRST IN HUMAN STUDY OF THE MENIN-MLL (KMT2A) INHIBITOR KO 539 IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ENTOSPLETINIB IN COMBINATION WITH INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN ADULTS WITH NEWLY DIAGNOSED NUCLEOPHOSMIN 1-MUTATED ACUTE MYELOID LEUKEMIA
- A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA
- A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG-221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION.
- PHASE I STUDY OF AUTOLOGOUS ACUTE MYELOGENOUS LEUKEMIA (AML) CELLS CONTAINING LENTIVIRUS ENGINEERING EXPRESSION OF IL-12
- RISK-STRATIFIED THERAPY FOR ACUTE MYELOID LEUKEMIA IN DOWN SYNDROME
View on source registry